Delivery Order SPE2DB20D1100-SPE2DB25FD7M1
- Not listed
- The U.S. Department of Defense Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $102,754.09 for Ultomiris 300 mg/3 mL vials on September 15, 2025. This firm fixed-price, competitively awarded contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery order is scheduled for...
- The Defense Logistics Agency awarded a $52,571.70 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Ultomiris (pegcetacoplan) 1,100 mg/11 ml vials on May 12, 2025, with an ultimate completion date of June 3, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ultomiris (pegtibatase alfa-ires) 1,100 mg/11 ml vials valued at $52,571.70 with a firm fixed price structure. This delivery order, awarded without set-aside designation through competitive procurement, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a $50,978.64 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ultomiris (pegcetacoplan) 1,100 mg/11 ml vials. The award was made on September 11, 2025, with an ultimate completion date of October 2, 2025, and the product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and represents a continuation of the company's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $87,619.50 to AmerisourceBergen Drug Corp for the supply of Ultomiris (pegcetacoplan) 1,100 mg/11 mL vials. This contract is a firm fixed price delivery order with no set-aside designation, issued competitively on June 11, 2025, with an ultimate completion date of July 3, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order...
- The Defense Logistics Agency awarded a $9,558.52 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Ultomiris 300 mg/3 ml vials. This non-competitive delivery order, with an ultimate completion date of September 29, 2025, represents a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency awarded a $74,874.86 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ULTOMIRIS (pegcetacoplan) 1,100 mg/11 ml vials on April 24, 2025, with an ultimate completion date of May 15, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical will be delivered to...
- The Defense Logistics Agency awarded a $131,429.25 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ultomiris (pegcetacoplan) 1,100 mg/11 mL vials. This contract, issued on August 15, 2025, with an ultimate completion date of September 8, 2025, represents a non-set-aside competitive award supporting federal pharmaceutical procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $26,285.85 for 1,100 mg/11 mL vials of Ultomiris, a complement inhibitor medication used to treat rare blood disorders and other conditions. This firm fixed-price, non-competitive set-aside contract was awarded on August 14, 2025, with an ultimate completion date of September 5, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Ultomiris (pegtibatimab alfa), a specialty pharmaceutical product, with a ceiling value of $26,285.85. This firm fixed-price delivery order is set to be completed by August 14, 2025, and represents performance at the vendor's corporate office location in Conshohocken, Pennsylvania. The award was competitively awarded with no set-aside designation,...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD7M1Delivery Order
The Defense Logistics Agency awarded a $26,285.93 delivery order to AmerisourceBergen Drug Corp for the supply of Ultomiris (pegcetacoplan) 300 mg/3 mL vials on July 30, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed price contract contains no set-aside designation and identifies AmerisourceBergen's Conshohocken, Pennsylvania facility as the place of performance. The delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. Ultomiris is a complement inhibitor utilized in the treatment of paroxysmal nocturnal hemoglobinuria and other complement-mediated disorders, reflecting the specialized pharmaceutical procurement requirements of the Defense Health Agency and other federal healthcare systems. As a major pharmaceutical distributor, AmerisourceBergen fulfills critical roles in the federal medical supply chain, delivering brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. The company's extensive portfolio of competitively awarded contracts with DLA demonstrates its capability to support military healthcare operations with firm fixed pricing arrangements across varying order values.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.3k | 7/30/25 |